Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Trial Profile

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Apr 2018 Planned End Date changed from 28 Feb 2019 to 28 Feb 2020.
    • 24 Apr 2018 Planned primary completion date changed from 28 Feb 2019 to 28 Feb 2020.
    • 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top